Stephen G Worthley, Gérard Helft, Roberto Corti, Matthew I Worthley, Derek P Chew, Zahi A Fayad, Azfar G Zaman, John T Fallon, Valentin Fuster, Juan J Badimon
Index: Pathophysiol. Haemost. Thromb. 36(1) , 9-17, (2007)
Full Text: HTML
The ability to modify the enzymatic processes involved in promoting atherosclerotic plaque disruption and to serially monitor atherosclerotic evolution could provide novel information in the management of patients with atherosclerosis. We studied the effects of a statin (atorvastatin) and its combination with an acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitor (avasimibe) on atherosclerotic regression and plaque stability as measured by matrix metalloproteinase 1 and 3 (MMP-1 and MMP-3) levels. Watanabe Heritable Hyperlipidemic (WHHL) rabbits treated with atorvastatin alone experienced an attenuated increase in atherosclerotic burden versus controls as determined by MR imaging. The mean vessel wall area (VWA) prior to drug therapy was 5.57 +/- 0.01 mm2. The VWA increased to 6.71 +/- 0.03 and 7.16 +/- 0.03 mm2, respectively, in atorvastatin-treated and control groups (p < 0.0001 for both). The combination of atorvastatin and avasimibe induced a significant regression of the previously established atherosclerotic lesions, with the VWA decreasing to 4.54 +/- 0.04 mm2 (p = 0.009). Atorvastatin alone induced a nonsignificant reduction in the percent staining of MMP-1 in atherosclerotic lesions, but the combination treatment with avasimibe led to a significant reduction versus controls (p = 0.005). However, a reduction in MMP-3 staining was significant for rabbits treated with both atorvastatin alone (p = 0.007) and in combination with avasimibe (p = 0.04) versus controls. In this animal model, the addition of avasimibe to atorvastatin has beneficial effects on both atherosclerotic plaque regression and stabilization.Copyright 2008 S. Karger AG, Basel.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Avasimibe
CAS:166518-60-1 |
C29H43NO4S |
Coronary circulatory function in patients with the metabolic...
2011-09-01 [J. Nucl. Med. 52(9) , 1369-77, (2011)] |
Avasimibe and atorvastatin synergistically reduce cholestery...
2002-09-06 [Eur. J. Pharmacol. 451(1) , 11-7, (2002)] |
Anti-atherogenic effects of the acyl-CoA:cholesterol acyltra...
2002-03-01 [Atherosclerosis 161(1) , 45-54, (2002)] |
Effects of avasimibe on cytochrome P450 2C9 expression in vi...
2004-12-01 [Drug Metab. Dispos. 32(12) , 1370-6, (2004)] |
New advances in lipid-modifying therapies for reducing cardi...
2002-01-01 [Cardiology 97(2) , 59-66, (2002)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved